These findings are consistent with the recent recommendations of using angiotensin system inhibitors, including angiotensin-converting enzyme inhibitors (ACEs) and angiotensin-II type 1 receptor blockers (ARBs) as a therapy in the management of hypertension caused by VEGFR-TKIs including sorafenib, sunitinib, tivozanib [16,20]. This evidence concerns the gene KDR and Hypertension.